Back Pain News and Research

Latest Back Pain News and Research

DAS Family Holdings invests in Medical Technologies Unlimited

David Schwedel confirmed that DAS Family Holdings, LP has invested approximately $4 million in Medical Technologies Unlimited, Inc., a developer of advanced medical devices.

5 Oct 2009

Nutra Pharma manufactures first commercial batch of Cobroxin

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first commercial batch of Cobroxin and has successfully released it for final distribution.

3 Oct 2009

iTech Medical provides update on MPR system

iTech Medical, Inc. (OTC Bulletin Board: IMSU; FWB: 0IM), a medical information technology company, today provided an update on the Company's clinical and regulatory plans for its proprietary Muscle Pattern Recognition (MPR) System.

1 Oct 2009

Stellartech and Orthomems to design and develop external reader device

Stellartech, a world leader in the design, development and contract manufacture of sophisticated medical systems, and OrthoMEMS, a medical device company focused on biomedical applications of patented MEMS (micro-electro-mechanical systems) and wireless technology from Cleveland Clinic, today announced a strategic alliance that is set to deliver a groundbreaking, commercial reader for wireless communication with a miniature implanted sensor in the spine.

1 Oct 2009

Strategies to facilitate new, rapid payment system for medical care

A new RAND Corporation study outlines methods that might be used to test a novel payment system for medical care that would provide doctors, hospitals and other health providers a set fee for treating an ailment such as hip replacement surgery.

30 Sep 2009

NINDS: $50 billion spent each year for low back pain

A study by researchers at The George Institute for International Health in Australia found that it is rare for patients presenting to PCPs with acute lower back pain to have previously undiagnosed serious diseases. The most common serious disease cause documented was vertebral fracture, with half of the cases identified at the time of initial consultation.

29 Sep 2009

Fear of back pain from care work is predictive of actually developing it

Whether from heaving, twisting, bending or bad lifting postures, it's well known that caring for the sick or elderly can lead to back pain. This often results in time off work or dropping out of caring professions altogether. Now Danish research published in the online open access journal BMC Musculoskeletal Disorders suggests that the fear of getting back pain from care work is predictive of actually developing it.

24 Sep 2009

Four percent annual growth for chronic pain drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).

23 Sep 2009

Decision Points helps patients with important medical decisions

Healthwise has released a new, interactive generation of its Decision Points to help people make better decisions with their doctors.

23 Sep 2009

Drug registration process for Nutra Pharma's pain reliever begins

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Canada and Europe for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

22 Sep 2009

Recession is contributing to acute physical pain for Americans: Survey

A new survey from the American Pain Foundation says economic pain from the recession is contributing to acute, or short-term, physical pain for Americans. According to the survey, released today during National Pain Awareness Month, 68 percent of people who experienced acute back pain or other minor muscle strains and sprains in the past year said that the recession caused, increased or affected their pain, often because of greater stress and working harder at home and on the job.

21 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

SI-BONE's summit to develop clinical diagnostic process for SI Joint pathology identification

SI-BONE, Inc. a San Francisco Bay-area, medical device company, announced the first ever meeting of thought leading spine surgeons to review data and develop a clinical diagnostic process for identification of SI Joint pathology, a frequent cause of low back pain.

17 Sep 2009

Somatic Systems launches its second Clinical Somatics Professional Training Program

Somatic Systems, Inc. is pleased to announce the launch of a second Clinical Somatics Professional Training Program this year. The program will begin December 5, and feature a convenient, innovative modular format to accommodate a variety of professional schedules.

16 Sep 2009

Somatic Systems accelerates efforts on projects to provide pain care services to the US Military

Somatic Systems, Inc. (PINKSHEETS: SMAS) stated that they have accelerated their efforts on their projects to provide pain care services to the US Military and establish Military health insurance coverage for Somatic Systems' powerful Clinical Somatics pain treatment method.

15 Sep 2009

Positive results from Merck's Phase IIB clinical study of odanacatib for treating osteoporosis

New data from a Phase IIB clinical study of odanacatib, Merck & Co., Inc.'s oral, once-weekly investigational treatment for osteoporosis, showed that when stopping treatment after two years, the increases in lower back (lumbar spine) bone mineral density (BMD) were reversed over the next year, while BMD at the hip (femoral neck) remained above levels observed at the start of the study.

15 Sep 2009

Spinal implants market to grow in the coming years: iData Research

According to a new market research report by iData Research, the leading international authority in medical device, dental and pharmaceutical market research, the U.S. market for spinal motion preservation devices is estimated to reach $2.54 billion by 2015. The global market for minimally invasive surgery (MIS) is also estimated to see double digit growth, with these two segments driving the overall market for spinal implants, MIS and VCF devices.

14 Sep 2009

Somatic Systems files financial reports with Pink Sheets

Somatic Systems, Inc. (PINKSHEETS: SMAS) announced that it has released its most recent financial reports, bringing its financial reporting status current on Pink Sheets.

14 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

FDA approves Supplemental New Drug Application for DOXIL

Centocor Ortho Biotech Products, L.P. today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for DOXIL (doxorubicin HCI liposome injection) in combination with docetaxel for the treatment of women with locally advanced and metastatic breast cancer.

10 Sep 2009